Roundtable Discussion: Discussing Targeted LNP Design to Minimize Immunogenicity, Maximize Safety, & Protect Sensitive Tissues for Extrahepatic Applications
- How can lipid chemistry and functional group modifications be leveraged to reduce toxicity and off-target effects while maintaining delivery efficiency?
- Which design strategies and targeting ligand modifications best balance tissue specificity, immunogenicity, and safety across sensitive extrahepatic targets?
- How can LNP formulations be engineered to mitigate immune recognition and anti-drug antibody formation to achieve tolerable repeat dosing?